Amarin Corp. (AMRN) Gets U.S. Patent for AMR101
Tweet Send to a Friend
Get Alerts AMRN Hot Sheet
Up)
Trade AMRN Now!
Amarin Corporation plc (Nasdaq: AMRN), reports that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical composition of Amarin's AMR101 based on U.S. Patent Application Serial No. 12/052,598, also known as the EPA with no DHA in a capsule application. Amarin announced on March 20, 2012, the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,188,146, is titled "Highly Purified Ethyl EPA and Other EPA Derivatives."
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin (AMRN) Vascepa sNDA Set for Oct. 16, 2013, According to FDA
- Amarin (AMRN) Vascepa Prescriptions Still Showing Strong Growth (GSK)
- Sarepta Therapeutics (SRPT) Says Eteplirsen Demonstrates a Continued Benefit on Walking Test Through 84 Weeks
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
